outcomes following BRCA testing in women with ovarian cancer and their female first-degree relatives. Two strategies are being compared: no testing versus BRCA testing. Estimates of cancer incidence and mortality, uptake and impact of risk reduction surgery and costs of BRCA testing, cancer treatment and palliative care were based on literature review. Outcomes are expressed as quality-adjusted life years (QALYs). Given the sensitivity analyses are conducted for key model parameters. RESULTS: We first evaluated the cost-effectiveness of gene testing in relatives of ovarian cancer patients with BRCA mutations. Results showed this was associated with an ICER below the UK cost-effectiveness threshold of £20,000 per QALY gained compared with no testing. Sensitivity analyses showed the results were robust. CONCLUSIONS: We demonstrate that gene testing in unaffected female first-degree relatives of women with ovarian cancer due to BRCA mutations is cost effective. The final results will consider the cost effectiveness of offering BRCA testing to all eligible ovarian cancer cases and their unaffected female first-degree relatives.

PCN169 BURDEN OF RENAL IMPAIRMENT: RELATIVE HEALTH CARE RESOURCE USE IN PROSTATE CANCER PATIENTS WITH BONE METASTASES
Qian Y1, Arellano E2, Gatta F3, Burke TP3, Holbrook TP4
1Amgen Inc., Thousand Oaks, CA, USA, 2Amgen (Europe) GmbH, Zug, Switzerland, 3Adelphi Real World, Bollington, UK
OBJECTIVES: Existing evidence suggests that around 49% of patients with bone metastases from solid tumors show evidence of renal impairment (eGFR<60mL/min/1.73m²) following diagnosis of bone metastases with approximately 80% of them developing chronic kidney disease. The objective of this analysis is to assess the economic burden of renal impairment in oncology patients using the most recent evidence. METHODS: Authors identified relevant studies using MEDLINE, EMBASE, and Cochrane databases. We included studies published between 2012 and 2021 that provided data on the incidence and health care resource use in oncology patients with bone metastases. RESULTS: Of 13,564 identified studies, 46 were selected (19 observational studies, 27 RCTs). Patients with bone metastases were reported to have an increased risk of inpatient visits of 63% (p < 0.001) compared to the control group (0.78 vs. 0.48 inpatient visits per patient per year). Additionally, the renal impairment group had a mean of 2.43 (p=0.027) more inpatient days per year than the control group (5.00 vs. 2.56 inpatient days per patient per year). It was also observed that the patients in the renal impairment group were less likely to have received chemotherapy (37% vs 47% received chemotherapy). CONCLUSIONS: Findings suggest an increase in health care utilization in the hospital setting in patients with bone metastases and renal impairment. In addition, compromised renal function in these patients may potentially have restricted the use of nephrotoxic chemotherapy agents.

PCN170 ESTIMATING THE VOI OF PIVOTAL STUDIES TOWARDS PREDICTIVE BIOMARKERS OF HIGH DOSE ALKYLATING CHEMOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER
Miguel Cases A1, Retiel VP2, van Harten WH3, Steuten LMG2
1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2University of Tuente, Enschede, The Netherlands
OBJECTIVES: To estimate the expected benefits from a pivotal randomised controlled trial of predictive biomarkers for high dose alkylating chemotherapy (HDAC) in triple-negative breast cancer (TNBC) and the potential economic value of HDAC and priority of further studies. METHODS: A markov decision model compared treating 40-year-old TNBC women with HDAC based on four predictive biomarker strategies: 1) BRCA1-like by MLPA testing, 2) BRCA1-like by aCGH testing, 3) strategy 1 followed by XIST and 53BP1 testing; and 4) strategy 2 followed by XIST and 53BP1 testing, versus treating all patients with standard chemotherapy. A Dutch societal perspective and a 20-year time horizon were used. Input data came from literature and expert opinions. We assessed four primary outcomes: the expected value of (partial) perfect information (EVPPI) if we expected the value of sample information (EVS) and the expected net benefit of sampling (ENBS) for the ongoing pivotal TNM trial (NC101057689) and/or potential future studies. RESULTS: The population EVPPI was €665 million (€). The EVPPI suggests prioritising further research towards effectiveness parameters, specifically prevalence and positive predictive value of the biomarkers; response rates in biomarker negative patients and TNBC unclassified patients, which are estimated to collectively have a value of information of €630M. The value of further research on transition probabilities is estimated at € 41M, followed by utilities at €34M and costs at €34M. Further information on transition probabilities could be gathered from the TNM trial and that of effectiveness parameters and costs from accompanying studies to this trial, altogether estimated to have an ENBS of €657 M. CONCLUSIONS: Further research on predictive biomarkers for HDAC should focus on gathering transition probability data from existing and planned trials and accompanying studies to derive data on other effectiveness parameters and costs.

PCN171 REAL WORLD DATA IN ONCOLOGY: THIRD- AND FOURTH-LINE TREATMENTS ADMINISTERED IN METASTATIC COLON-RECTAL CANCER (mCRC)
Heman F1, Ripellino C, Visentin E
1CISI Medical Research S.r.l., Milan, Italy
OBJECTIVES: The objective of this study was to assess the oncologists’ real clinical practice in the management of mCRC patients, with a focus on the 3rd, 4th and later lines of therapy in Italy. METHODS: Data presented in this study were collected from medical records obtained by Italian oncologists on mCRC patients between March and April 2014 and retrieved from an extra boost of ONCOCVIEW database. ONCOCVIEW is an ongoing syndicated study on cancer treatment in the hospital setting, based on the collection of patient questionnaires. Patients inclusion criteria were the presence of an mCRC diagnosis, 3rd or later actual therapy line and no participation in a phase II or III clinical study. Information collected included patient demographic characteristics, mCRC Characteristics (TNM Classification, Karnofsky performance status scale and mutation analyses) and treatments (actual and previous schedules, dosages and durations). Furthermore, the overall survival of the “Rechallenge” occurrence was considered in the 3rd or later line of treatment of drugs previously used, has been performed. RESULTS: 261 patients diaries have been collected: 218 out of 261 patients were in third line of treatment, while 43 patients were in 4th or later treatment line. The most used threshold scheme was Capetexibine alone (63 patients), while the most used schema in fourth line was a combination of Fluorouracil and Folinic Acid (7 patients). About 40% of molecules administered in 3rd line and 67% of molecules administered in 4th line were included in previous lines. CONCLUSIONS: Results from the present study underline the unmet medical need in 3rd or later line of treatment of mCRC patients and the need for additional evidence-based treatment options.

PCN172 BURDEN OF DRUG WASTE IN ONCOLOGY: OPTIMIZATION OF RESOURCE USE
Castro AP1, Alves AF1, Paaldea A, Clark LCO, Bueno CC, Minowa E
1Evidências Credibilidade Científica, São Paulo, Brazil
OBJECTIVES: Minimizing waste of the use of drugs allows optimizing available resources in a scarce environment. Grouping patients may be an alternative to reduce drug waste in oncology. The economic impact of streamlining form of dispensation and percentage of drug wastage of the total drug expenditure in supplementary health system. METHODS: Patients receiving neoplastic treatment for breast cancer and breast cancer were eligible and selected retrospectively from the private market administrative claims database (Evidencias database). Name and any other personal identifiable data at the database’s date of administration were collected from 3 selected private institutions considering large to small size in terms of patients. Drug waste of was calculated and it was defined as unavoidable or inappropriate clearance of partially drug use. All analyses were calculated assuming minimization of waste by optimizing fully drug among group patients. Costs were derived from Simpro table. Exchange rate used was 1 US Dollar = 2.20BRL. RESULTS: There were 1081 patients in all 3 hospital centers. About 2% to 8% of the total drug expenditure, regarding on the antineoplastic used. Five of the 11 drugs did not cause savings due to small number of patients receiving these treatments. CONCLUSIONS: Grouping patients for drug wastage minimization is an effective way to reduce costs. Furthermore, savings can be increased by gathering patients of different diseases.

PCN173 RESOURCES UTILIZATION FOR THE INVESTIGATION OF PULMONARY NODULES IN A UNIVERSITY HOSPITAL CENTER IN QUEBEC, CANADA
Ghazieh Laiherbe A1, Bergere E2, Lachaine J3, Diel I1
1University of Montreal, Montreal, QC, Canada, 2CHUM Hotel-Dieu, Montreal, QC, Canada
OBJECTIVES: Lung cancer is the leading cause of death among cancer patients; therefore, the detection of malignant nodules is currently a major challenge. The objective of this study was to measure the health care resources used for the investigation of pulmonary nodules. METHODS: A retrospective medical chart review was conducted at the CHUM-Hotel-Dieu in Montreal, Canada. Eligible patients were selected consecutively using the electronic appointment book of the pulmonary clinic, from January 1st 2011 to May 31st 2012. Inclusion criteria were: 40-year-old and over, presenting a pulmonary nodule ranging from 0.8 to 3.0 cm with no prior history of cancer in the last 5 years and no history of lung cancer. Patient’s demographics, nodule characteristics, medical information and resources utilization were extracted for each patient. RESULTS: A total of 47 patients (23 women and 24 men, mean age = 64) were included in the analysis. The mean nodule size was 1.8 cm. Thirteen patients (28%) had a benign nodule and 34 (72%) had a malignant nodule. The most frequent non-invasive procedures were Thorax CT-Scan, PET-Scan and Chest X-ray performed at least once in respectively 96%, 85% and 77% of patients. The minimally invasive procedures (bronchoscopy and tracheorhinic needle biopsy) and the invasive procedures (thorascopy and thoratomy) were mostly performed in patients who were eventually diagnosed with a lung cancer. On average, patients with a benign nodule underwent 0.77 minimally invasive or invasive procedures vs. 1.94 for patients with a malignant nodule (p=0.001). A total amount of €34M. was deployed for the investigation of pulmonary nodules. This study tends to demonstrate that minimally invasive and invasive procedures are mostly deployed for the diagnosis of malignant nodules.